AIMZ Investment Advisors LLC lessened its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 11.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 132,020 shares of the company’s stock after selling 17,272 shares during the period. Teva Pharmaceutical Industries accounts for 1.9% of AIMZ Investment Advisors LLC’s holdings, making the stock its 16th biggest holding. AIMZ Investment Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $2,502,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Crossmark Global Holdings Inc. acquired a new stake in Teva Pharmaceutical Industries in the third quarter worth $393,000. Gabelli Funds LLC grew its holdings in Teva Pharmaceutical Industries by 33.3% in the third quarter. Gabelli Funds LLC now owns 20,000 shares of the company’s stock worth $352,000 after purchasing an additional 5,000 shares during the period. Candriam Luxembourg S.C.A. grew its holdings in Teva Pharmaceutical Industries by 337.1% in the third quarter. Candriam Luxembourg S.C.A. now owns 51,908 shares of the company’s stock worth $914,000 after purchasing an additional 40,033 shares during the period. FDx Advisors Inc. grew its holdings in Teva Pharmaceutical Industries by 17.9% in the third quarter. FDx Advisors Inc. now owns 89,785 shares of the company’s stock worth $1,580,000 after purchasing an additional 13,658 shares during the period. Finally, HL Financial Services LLC grew its holdings in Teva Pharmaceutical Industries by 68.7% in the third quarter. HL Financial Services LLC now owns 35,840 shares of the company’s stock worth $631,000 after purchasing an additional 14,601 shares during the period. 58.22% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have commented on the stock. Goldman Sachs Group upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 price target for the company in a report on Friday, December 15th. Cantor Fitzgerald set a $18.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Thursday, December 28th. BTIG Research set a $16.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Tuesday, November 28th. ValuEngine cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Vetr cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $21.73 price target for the company. in a report on Monday. Ten research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $20.81.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The company had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the firm earned $1.38 earnings per share. The firm’s revenue was down 15.9% on a year-over-year basis. research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.31 EPS for the current fiscal year.
In related news, EVP Mark Sabag sold 5,050 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $19.68, for a total transaction of $99,384.00. Following the transaction, the executive vice president now directly owns 44,517 shares of the company’s stock, valued at $876,094.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 7,636 shares of company stock worth $149,390 over the last three months. 7.10% of the stock is owned by insiders.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.